Key point

1
Key point

• Quinapril continues to show improved clinical
  benefit with reductions in BP, reduced
  microalbuminuria, and reduced cardiovascular
  events.
• Quinaprils high tissue binding, shows vascular
  biological benefits in pathobiological studies.
• The combination of ACEI with other agents is
  outlined in the recent American JNC VII
  guidelines for hypertension.
• Global risk reduction continues to be the major
  target in reducing cardiovascular events.

2
(No Transcript)
3
(No Transcript)
4
(No Transcript)
5
(No Transcript)
6
(No Transcript)
7
(No Transcript)
8
(No Transcript)
9
(No Transcript)
10
(No Transcript)
11
(No Transcript)
12
(No Transcript)
13
(No Transcript)
14
(No Transcript)
15
(No Transcript)
16
(No Transcript)
17
(No Transcript)
18
(No Transcript)
19
(No Transcript)
20
(No Transcript)
21
(No Transcript)
22
(No Transcript)
23
(No Transcript)
24
(No Transcript)
25
(No Transcript)
26
(No Transcript)
27
(No Transcript)